Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-8080 plus dalpiciclib in unresectable or metastatic breast cancer (phase Ib/II)
CTR20233951Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Jan 2024
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-8080 in breast cancer, sponsored by Shandong Sende. Started Jan 2024; status: active.
02
Drugs
HRS-8080
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20233951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233951.